{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:07:34Z","timestamp":1778803654395,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jiac.2026.102985","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T14:50:37Z","timestamp":1777733437000},"page":"102985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Retrospective comparative study of myelosuppression associated with linezolid and tedizolid therapy"],"prefix":"10.1016","volume":"32","author":[{"given":"Yuichi","family":"Shibata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Asai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao","family":"Hagihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8876-6411","authenticated-orcid":false,"given":"Hiroshige","family":"Mikamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2026.102985_bib1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1086\/338403","article-title":"Thrombocytopenia associated with linezolid therapy","volume":"34","author":"Attassi","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2026.102985_bib2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jiac.2019.07.022","article-title":"Relationship between cytopenia and gestational age in infants and neonates treated with linezolid therapy","volume":"26","author":"Shibata","year":"2020","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2026.102985_bib3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1086\/498509","article-title":"High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease","volume":"42","author":"Wu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2026.102985_bib4","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/jac\/dkt133","article-title":"High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia","volume":"68","author":"Nukui","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2026.102985_bib5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2007.04.005","article-title":"The site of action of oxazolidinone antibiotics in living bacteria and in human Mitochondria","volume":"26","author":"Leach","year":"2007","journal-title":"Mol Cell"},{"key":"10.1016\/j.jiac.2026.102985_bib6","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jiac.2018.01.010","article-title":"Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan - results of a randomised, multicentre phase 3 study","volume":"24","author":"Mikamo","year":"2018","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2026.102985_bib7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.cmi.2025.10.007","article-title":"Efficacy and safety of tedizolid in the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis of randomised controlled trials","volume":"32","author":"Sevilla","year":"2026","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2026.102985_bib8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/INF.0000000000003010","article-title":"Safety and efficacy of oral and\/or intravenous tedizolid phosphate from a randomized phase 3 trial in adolescents with acute bacterial skin and skin structure infections","volume":"40","author":"Bradley","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jiac.2026.102985_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02252-18","article-title":"Efficacy and safety of tedizolid phosphate versus linezolid in a randomized phase 3 trial in patients with acute bacterial skin and skin structure infection","volume":"63","author":"Lv","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2026.102985_bib10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/INF.0000000000004807","article-title":"A phase 3 study of the safety and efficacy of tedizolid phosphate in patients <12 years of age with acute bacterial skin and skin structure infections","volume":"44","author":"Mngqibisa","year":"2025","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jiac.2026.102985_bib11","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","article-title":"Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial","volume":"14","author":"Moran","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2026.102985_bib12","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections","volume":"309","author":"Prokocimer","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jiac.2026.102985_bib13","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10156-010-0182-1","article-title":"Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy","volume":"17","author":"Takahashi","year":"2011","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2026.102985_bib14","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jiac.2022.04.003","article-title":"Correction of thrombocytopenia caused by linezolid with scheduled sequential tedizolid use in patients with vertebral osteomyelitis by antibiotic resistant Gram-positive organisms","volume":"28","author":"Ueda","year":"2022","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2026.102985_bib15","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1128\/AAC.03431-14","article-title":"Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment","volume":"58","author":"Flanagan","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2026.102985_bib16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.jiac.2026.102985_bib17","first-page":"31","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.jiac.2026.102985_bib18","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1177\/13524585221085733","article-title":"Recommendations for the use of propensity score methods in multiple sclerosis research","volume":"28","author":"Simoneau","year":"2022","journal-title":"Mult Scler"},{"key":"10.1016\/j.jiac.2026.102985_bib19","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s10156-010-0188-8","article-title":"Chronic liver disease increases the risk of linezolid-related thrombocytopenia in methicillin-resistant staphylococcus aureus-infected patients after digestive surgery","volume":"17","author":"Ikuta","year":"2011","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2026.102985_bib20","doi-asserted-by":"crossref","first-page":"837","DOI":"10.12669\/pjms.293.2925","article-title":"Efficacy of linezolid on gram-positive bacterial infection in elderly patients and the risk factors associated with thrombocytopenia","volume":"29","author":"Bi","year":"2013","journal-title":"Pak J Med Sci"},{"key":"10.1016\/j.jiac.2026.102985_bib21","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s11096-014-9961-6","article-title":"Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients","volume":"36","author":"Hirano","year":"2014","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.jiac.2026.102985_bib22","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jiac.2016.05.003","article-title":"A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia","volume":"22","author":"Hanai","year":"2016","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2026.102985_bib23","first-page":"CD002042","article-title":"Transfusion thresholds and other strategies for guiding red blood cell transfusion","volume":"10","author":"Carson","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jiac.2026.102985_bib24","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1128\/AAC.03684-14","article-title":"Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function","volume":"59","author":"Flanagan","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2026.102985_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiac.2024.12.011","article-title":"Clinical efficacy and safety assessment of tedizolid using therapeutic drug monitoring","volume":"31","author":"Shibata","year":"2025","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2026.102985_bib26","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/phar.1337","article-title":"Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug","volume":"34","author":"Flanagan","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jiac.2026.102985_bib27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40360-021-00479-w","article-title":"Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients","volume":"22","author":"Kawasuji","year":"2021","journal-title":"BMC Pharmacol Toxicol"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X26000838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X26000838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:12:13Z","timestamp":1778800333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X26000838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1341321X26000838"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2026.102985","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retrospective comparative study of myelosuppression associated with linezolid and tedizolid therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2026.102985","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102985"}}